This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Vaxzevria | |
|---|---|
| Name | Vaxzevria |
| Type | vaccine |
| Target | Severe acute respiratory syndrome coronavirus 2 |
| Developer | AstraZeneca |
| Administered | Intramuscular |
Vaxzevria is a viral vector vaccine developed to prevent COVID-19, created by AstraZeneca in collaboration with the University of Oxford and the Jenner Institute. It has been evaluated in clinical trials coordinated across institutions such as the National Health Service, the NIHR, and multinational consortia involving sites in United Kingdom, Brazil, South Africa, and United States. Regulatory submissions were made to agencies including the European Medicines Agency, the Medicines and Healthcare products Regulatory Agency, and the World Health Organization for emergency use and broader licensure.
Vaxzevria is indicated for active immunization against disease caused by Severe acute respiratory syndrome coronavirus 2 in adults, with dosing regimens considered by advisory bodies such as the Joint Committee on Vaccination and Immunisation, the Centers for Disease Control and Prevention, and the Advisory Committee on Immunization Practices. Clinical deployment involved mass vaccination campaigns organized by ministries such as the Department of Health and Social Care and public health agencies like Public Health England and ANVISA. Use has been incorporated into national strategies alongside other vaccines like those from Pfizer–BioNTech, Moderna, and Johnson & Johnson, and coordinated with distribution networks including COVAX, the European Commission, and bilateral agreements with governments such as India and Brazil.
Efficacy estimates derived from randomized controlled trials and real-world studies were reported by investigators collaborating across universities such as University of Oxford, Imperial College London, and University of São Paulo and published in journals including The Lancet and The New England Journal of Medicine. Reported efficacy against symptomatic infection varied by study and interval between doses, with effectiveness analyses from population cohorts in Scotland, England, and Israel compared to data from phase III trials in United Kingdom and Brazil. Studies assessing variants involved sequencing efforts by organizations like GISAID, Public Health England, and research groups at University of the Witwatersrand examining performance against lineages such as B.1.1.7, B.1.351, and P.1. Vaccine effectiveness estimates were integrated into modeling by groups at Imperial College London, London School of Hygiene & Tropical Medicine, and Centers for Disease Control and Prevention to inform policy.
Safety profiles were assessed in trials overseen by institutional review boards at institutions including the University of Oxford, LSHTM, and ethics committees in Brazil, with pharmacovigilance conducted by agencies such as the European Medicines Agency and the MHRA. Common adverse events reported in trials included local and systemic reactions monitored alongside serious adverse events such as thrombotic events investigated by researchers at Aarhus University, Karolinska Institute, and clinical teams at King's College Hospital. Signal detection and causality assessments involved collaboration between the World Health Organization, the European Centre for Disease Prevention and Control, and national regulators like Health Canada. Risk communication included statements from leaders such as the Director-General of WHO and ministers in countries like Germany, France, and United Kingdom.
The vaccine uses a replication-deficient simian adenovirus vector derived from Chimpanzee adenovirus ChAdOx1, encoding the SARS‑CoV‑2 spike glycoprotein first characterized by teams at University of Hong Kong, Fudan University, and structural groups at University of Oxford. Its formulation includes excipients selected using standards from pharmacopeias such as the European Pharmacopoeia and quality guidance from agencies like FDA and EMA. Mechanistic studies were conducted with immunology groups at NIH, Scripps Research Institute, and Institut Pasteur to evaluate humoral and cellular responses measured by assays developed at Fred Hutchinson Cancer Research Center and Imperial College London.
Manufacturing partnerships included contract manufacturers such as Serum Institute of India, Catalent, and facilities coordinated by AstraZeneca and technology transfer programs involving Oxford Biomedica. Supply chains engaged organizations like GAVI, UNICEF, and logistics providers working with ports in Rotterdam, Mumbai, and Baltimore. Cold chain requirements were aligned with standards from WHO and national immunization programs in countries including United Kingdom, South Africa, and Brazil. Allocation frameworks referenced multilateral arrangements under COVAX and bilateral procurement agreements negotiated with entities such as the European Union and national procurers.
Emergency use listings and conditional approvals were granted by regulators including the European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Therapeutic Goods Administration, and the World Health Organization Strategic Advisory Group of Experts, with advisory recommendations from committees like the Joint Committee on Vaccination and Immunisation and the Advisory Committee on Immunization Practices. National immunization schedules in countries such as United Kingdom, India, Chile, and South Africa incorporated guidance on dosing intervals and contraindications issued by health ministries and public health bodies.
Development originated at the University of Oxford's Jenner Institute with principal investigators collaborating with entities like AstraZeneca and funders including Wellcome Trust, UK Research and Innovation, and the Bill & Melinda Gates Foundation. Clinical trials were registered and run across sites in United Kingdom, Brazil, South Africa, and United States, with data disseminated through preprints on platforms such as medRxiv and peer-reviewed journals including The Lancet. Manufacturing scale-up involved agreements with manufacturers such as the Serum Institute of India and supply deals negotiated with the European Commission and national governments including United Kingdom and India. Political and public health responses engaged leaders and institutions including the Prime Minister of the United Kingdom, the European Commission President, and the Director-General of WHO in discussions about deployment and prioritization.